Date: 2011-10-00
Type of information: Fundraising
Company: Viroblock (Switzerland)
Investors:
Amount: CHF 3.3 million (€2.6 million)
Funding type: series C financing round
Planned used: These funds allow Viroblock to complete the development of its anti-viral face-mask and start commercialization in 2012. Unlike other face-masks, the Viroblock mask can kill enveloped viruses, such as H1N1, H5N1 and SARS, on pass through air.
Others: Viroblock, a company with a highly innovative, broadly applicable anti-viral air filtration technology, initially focused on development and commercialization of anti-viral face-masks, has announced the successful closure of a 3.3 million CHF Series C financing round. The financing round was led by Dr Peter Pfister and Dr Erich Platzer from the StartAngels Network, with strong support from new and existing investors.
Therapeutic area: Infectious diseases
